Archive | Updates

RSS feed for this section

Pharmaceutical Policy

Is Real-World Evidence all it’s trumped-up to be?

10 Apr
multiplechro

There’s so much discussion around Big Data and Real-World Evidence (RWE) in improving access to medicines. RWE is clinical data collected after the publication of clinical trials used for marketing authorization. Sources may include health insurance claims databases, patient registries, hospital patient records, among others. Clinical trials are by design the gold standard for new […]

Are access professionals recognised internationally for improving patient lives?

08 Mar

There’s so much incredible work happening in Africa and the Middle East! Every trip to the region leaves us inspired that access to medicines will continue to improve thanks to skilled and energetic access professionals. These are professionals in pharmaceutical companies, health insurance companies, government institutions, patient organisations, and independent researchers devoted to improving access […]

Closing out 2017

15 Dec
onesignalnotificationincon

2017 was an exciting year! As we take a look back at our activities, I’m excited that we completed various projects aimed at strengthening pharmaceutical markets in Africa and the Middle East. In the process, we engaged stakeholders across the spectrum of pharmaceutical markets – government institutions, multilateral agencies, patient organisations, donor agencies, pharma and […]

C&C at ISPOR in Glasgow

11 Oct
ISPOR

C&C at ISPOR in Glasgow C&C will be at ISPOR Glasgow in just a few weeks. Will you? We’re presenting results of our recent work for Clients in Sub-Saharan Africa and the Middle East. We put great effort into analysing new health technologies, determining their budget impact in various markets, and assessing market access opportunities. […]

Does the pharmaceutical industry bribe the FDA?

09 Aug
fda-logo-small

It’s not the type of question we’re asked every day, so it sparked our interest, particularly the assumption that something like this is possible. Opinion on the subject is divided. They range from ideas that anything related to the pharmaceutical industry is tainted, in this case the FDA, to opinions from scientists and policy experts […]

South Africa’s Private Health Insurance Industry: A Strategic National Asset under Threat?

11 Jul
Emergency

South Africa’s Cabinet of Ministers recently approved a White Paper on National Health Insurance aimed at moving the policy of universal health coverage further down the road. A National Health Insurance system would result in an integrated healthcare system founded on the principles of solidarity and redistribution of healthcare resources. The basic idea is that […]

WHO’s serious reservations on Value-Based Pricing: Conflicts and Nuances

08 Jun
WHO Fair Pricing Forum Carapinha & Company

On May 10 and 11, the WHO Fair Pricing Forum met to discuss improvements to medicine pricing practices and pricing approaches that balance public health needs and incentives for pharmaceutical research and development. The Forum was established to facilitate the exchange of insights on fairer medicine pricing systems, identification of research gaps to support improvements, […]

The Globalization of NICE’s Health Technology Appraisals

01 May
NICE-Small

The National Institute for Health and Care Excellence (NICE) in England often comes up in conversations on medicine reimbursement. The sequence of events goes something like this: a new medicine is planned for launch in a growth market (mostly middle-income countries), but the government and private health insurance companies are uncertain of its economic and […]

En garde QALY! Is your end nigh?

05 Apr
qalys

The Spanish Ministry of Health recently rejected the use of QALYs in cost-effectiveness analyses. At issue is the subjective nature of the parameters used to develop the QALY. The Quality-Adjusted Life-Years (QALY) is a product of the change in utilities associated with a treatment multiplied by the time of treatment exposure. The QALYs gained combined […]

Carapinha Logo